CRT

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Retrieved on: 
Monday, February 19, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, NSCLC, Fever, Progression-free survival, PFS, AstraZeneca, Heart, Periodic breathing, QT interval, MD, Chemoradiotherapy, Cough, Pemetrexed, Winship Cancer Institute, QT, OS, Electrolyte, Cardiomyopathy, Lung cancer, Safety, Emory University, CRT, LAURA, ILD, Patient, LVEF, Brain, Pharmaceutical industry

In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.

Key Points: 
  • In addition, TAGRISSO plus chemotherapy was recently approved in the US based on the FLAURA2 Phase III trial.
  • Interstitial lung disease (ILD)/pneumonitis occurred in 4% of the 1813 TAGRISSO-treated patients; 0.4% of cases were fatal.
  • TAGRISSO is the only targeted therapy to improve patient outcomes in both early-stage disease in the ADAURA Phase III trial and late-stage disease in the FLAURA Phase III trial and FLAURA2 Phase III trial .
  • AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

UltraNav Transseptal System will present at "Best Interesting Case" at CRT

Retrieved on: 
Tuesday, March 5, 2024
Catheter, Multimedia, Physician, Cardiology, ICE, International Society, Electrophysiology, Safety, DIB, Anesthesia, Nursing, CRT, Patient, Journal, Heart, TEE, Learning

SCOTTSDALE, Ariz., March 5, 2024 /PRNewswire/ -- Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in transseptal procedures, including delivery of catheters to the left atrium without the need for TEE and anesthesia, will be featured throughout the 2024 Cardiovascular Research Technologies Meeting (CRT) next week, including as a "Best Interesting Case," at Innovations Hub, Mar. 10 9:43-9:51am ET and 10:55-11:10am ET; Best Interesting Case, Mar 10 2:12-2:20pm ET; and Valve and Structural Innovation Pipeline, Mar. 12, 10:47-10:55am ET.

Key Points: 
  • 10 9:43-9:51am ET and 10:55-11:10am ET; Best Interesting Case, Mar 10 2:12-2:20pm ET; and Valve and Structural Innovation Pipeline, Mar.
  • UltraNav improves the safety and accuracy of transseptal procedures by enabling better visualization of the catheter, needle, and needle tip.
  • Dr. Nabil Dib, founder of Dib UltraNav Medical and inventor of the UltraNav Transseptal Catheter System, will present at CRT.
  • His mission when developing the UltraNav system was to increase the safety and accuracy of structural transseptal heart procedures, which are on the increase.

Impulse Dynamics Completes $136M Financing Round

Retrieved on: 
Wednesday, February 14, 2024
CCM, NYHA, Investment, Quality of life, Trial of the century, AIM, Feedback, Heart failure, Safety, Attention, ICD, CRT, Patient, Guideline, Clinical trial, HF, Heart, EF

The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.

Key Points: 
  • The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.
  • This substantial investment reflects investor confidence in, and commitment to, the company’s vision and expansion.
  • “This round of funding will accelerate our business, both commercially and with our pipeline of advanced technology innovation,” said Jason Spees, CEO of Impulse Dynamics.
  • “We are thrilled by the ongoing support from top-tier investment groups for Impulse Dynamics,” said Shlomi Nachman, Chairman of the Board.

Yachting at the heart of economic challenges in the region Sud and Monaco

Retrieved on: 
Friday, February 9, 2024
Workforce, Policy, PACA, Tourism, Principality, Yacht club, YCM, Pleasure, CRT, Ferretti Group, Economic development, Monégasque

This is what emerges from the economic symposium 'La Belle Classe Superyachts', organized by the Yacht Club de Monaco.

Key Points: 
  • This is what emerges from the economic symposium 'La Belle Classe Superyachts', organized by the Yacht Club de Monaco.
  • At the center of the event is the economic impact of yachting on a global level with a focus on the southern region of France and the Principality.
  • The yachting sector numbers 411 establishments or 3.7% of total businesses in the Principality, and 1,429 jobs, representing 2.4% of Monaco’s workforce.
  • Specialised design activities alone represent over 20 million euros of yachting revenue in 2022.

Best’s Special Report: AM Best Updates Net Capital Charge Tables Associated With Fannie-Freddie Mortgage Risk Transfers

Retrieved on: 
Wednesday, February 7, 2024
Insurance, Professional Services, Transfer, Freddie Mac, Table, CIRT, News, Capital, Publication, ACIS, Fannie Mae, ALL, CRT

These tables also highlight some of the key components of the factor-based method used to calculate net capital charges in the Best’s Capital Adequacy Ratio (BCAR) model.

Key Points: 
  • These tables also highlight some of the key components of the factor-based method used to calculate net capital charges in the Best’s Capital Adequacy Ratio (BCAR) model.
  • The net capital charge of CRT transactions is represented as B5m—mortgage-related net loss and LAE reserves risk—in the net required capital formula that is part of BCAR.
  • For this Best’s Special Report, “Updated Net Capital Charge Tables for ACIS/CIRT Reinsurance Transactions,” AM Best has selected approximately half the 164 CRT transactions effective through December 2023 to calculate the net capital charges associated with individual layers of the CRT transactions.
  • AM Best publishes these net capital charge tables semi-annually, using the most current performance data available from the government-sponsored enterprises’ websites.

Enact Completes Forward XOL Reinsurance Transaction as Part of its Diversified Credit Risk Transfer Program

Retrieved on: 
Thursday, February 1, 2024
ACT, Security (finance), Freddie Mac, Failure, Government, COVID-19, Uncertainty, Annual report, Communication, Federal Housing Administration, Fannie Mae, Risk, CRT, Insurance

This credit risk transfer (CRT) transaction covers a portion of expected new insurance written for the 2024 book year (policies written from January 1, 2024 through December 31, 2024), and is effective January 1, 2024.

Key Points: 
  • This credit risk transfer (CRT) transaction covers a portion of expected new insurance written for the 2024 book year (policies written from January 1, 2024 through December 31, 2024), and is effective January 1, 2024.
  • Reinsurance coverage is provided by a panel of reinsurers each currently rated “A-” or better by Standard & Poor’s or A.M. Best Company, Inc.
    “We’re pleased to have completed this XOL transaction,” said Rohit Gupta, President and CEO of Enact.
  • "Enact continues to be a market leader with its comprehensive CRT program and this transaction further reflects our ability to distribute and minimize credit risk and enhance our capital efficiency.
  • Enact is well-positioned to continue delivering value for our customers and stakeholders."

PennyMac Mortgage Investment Trust Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Thursday, February 1, 2024
REIT, Finance, Banking, Professional Services, Construction & Property, PMT, PennyMac Financial Services, MSR, UPB, Investment, Interest rate, Corporation, Credit, Sale, CRT, Security (finance)

PennyMac Mortgage Investment Trust (NYSE: PMT) today reported net income attributable to common shareholders of $42.5 million, or $0.44 per common share on a diluted basis for the fourth quarter of 2023, on net investment income of $84.8 million.

Key Points: 
  • PennyMac Mortgage Investment Trust (NYSE: PMT) today reported net income attributable to common shareholders of $42.5 million, or $0.44 per common share on a diluted basis for the fourth quarter of 2023, on net investment income of $84.8 million.
  • PMT previously announced a cash dividend for the fourth quarter of 2023 of $0.40 per common share of beneficial interest, which was declared on December 6, 2023, and paid on January 26, 2024, to common shareholders of record as of December 29, 2023.
  • “Book value per share net of the dividends was up 2 percent from the prior year end, driven by both PMT’s strong financial performance as well as our unwavering commitment to managing interest rate risk.
  • At the same time, we will remain disciplined in our approach to managing capital and interest rate risk, positioning PMT to continue delivering attractive risk-adjusted returns to its shareholders.”
    The following table presents the contributions of PMT’s segments, consisting of Credit Sensitive Strategies, Interest Rate Sensitive Strategies, Correspondent Production, and Corporate:

Global Cardiac Bio Implant Devices Market Size and Forecast Report 2023: A $60+ Billion Industry by 2030 - Growing Attractiveness of Bio-implant Treatments Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Biotechnology, Health, Cardiology, Medical Devices, Ageing, Diabetes, Obesity, Moyamoya disease, American Heart Association, Woman, Arthroscopy, Beauty, Binge drinking, Incidence, Cardiac catheterization, CRT, Angiography, Smoking, Application, Heart failure, Element, Echocardiography, ISR, USD, Cardiac resynchronization therapy, IHD, Diagnosis, Prevalence, Medical device

The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Cardiac Bio-Implants Device Market size is estimated to be US$ 60.20 Billion by 2030.
  • The global cardiac bio-implants market changed into worth USD 34.70 Billion in 2022.
  • The growth of the Cardiac Catheterization laboratory market is primarily fueled by the increasing prevalence of cardiovascular disorders and advancements in Cardiac Catheterization lab technology.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Global Head-Up Display Market Forecast to 2028: Europe Leads Head-Up Display Market with Significant Innovation and Adoption in Luxury, Premium Vehicles

Retrieved on: 
Thursday, January 11, 2024
LCD, Aviation, Liquid-crystal display, GPS, CRT, Application, Component, Accident, Insurance, LCOS, Liquid crystal on silicon, HUD, Digital, Safety, USD, DMD, Region, Convention (norm), Growth

The global head-up display market is expected to reach USD 3.3 billion by 2028 from USD 1.5 billion in 2023, at a CAGR of 16.7% during the 2023-2028 period.

Key Points: 
  • The global head-up display market is expected to reach USD 3.3 billion by 2028 from USD 1.5 billion in 2023, at a CAGR of 16.7% during the 2023-2028 period.
  • Head-up displays (HUDs) have emerged as a crucial technology in mitigating driver distractions and enhancing safety, thus driving demand in the market.
  • Europe Leads Head-Up Display Market with Significant Innovation and Adoption in Luxury, Premium Vehicles
    During the forecast period, Europe is poised to maintain its position as the dominant market for head-up displays, backed by its strong luxury and premium automotive manufacturing base.
  • This report offers key insights into internal market dynamics, growth factors, and barriers, accompanied by detailed analysis of market segmentation and regional diversification.